Overview

Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
To determine how long Gemcitabine and Bevacizumab will stop the cancer from growing in patients with advanced breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Genentech, Inc.
Treatments:
Bevacizumab
Gemcitabine